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by
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Research Advisor: Dr. S. Joshua Swamidass
Copy Number Variations (CNVs) are a significant source of human genetic diversity and
are believed to be responsible for a wide variety of phenotypic variation. Recent advances
in microarray-based genomic hybridization techniques have facilitated CNV analysis as a
viable diagnostic technique in the clinic, and several public databases of well-characterized
CNVs are being compiled, but a standard for interpreting uncharacterized CNVs has yet to
emerge.
This thesis examines the clinical interpretation of uncharacterized CNVs as a multiple
instance binary classification problem. We analyze the current state of clinical techniques,
then present and test a novel, statistical approach to the problem.
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Chapter 1
Introduction
1.1 Background
Copy Number Variations (CNVs) are a form of structural variation in a genome, where large
segments of DNA have different numbers of copies between individual organisms of the
same species. Segments of the genome with increased copy number are called duplications;
decreases in copy number are referred to as deletions. An organism’s CNVs are either
inherited or the result of a de novo mutation.
CNVs are common in humans[1] and account for a significant amount of genetic variability[2].
Some hypothesize, therefore, that CNVs might explain phenotypic variation among hu-
mans, specifically as they relate to an individual’s susceptibility to disease[3, 4]. Con-
sequently, patient CNV data is becoming for frequently used in the clinic as a tool for
diagnosis. To this end, several databases of characterized CNVs are maintained, includ-
ing the Database for Genomic Variants[5], the UCSC Genome Browser[6], CNVVdb[7],
CHOPPY[8], DECIPHER[9], and the NCBI dbVar database[10]. However, the majority of
CNVs encountered in the clinic are still uncharacterized, that is, with no proven association
to disease.
1.2 Case Study
This case, taken from a 2009 study by Tsuchiya et al. [11], represents a common clinical
scenario. A patient (case 2 in Table 1.1) with a family history of learning disabilities arrives
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at the clinic showing symptoms of developmental delay. After running several other tests,
the physician orders a screen of the patient’s CNVs. A deletion of 810 kilobases is identified
on chromosome 8, then confirmed with a secondary test. This CNV is entirely contained
in CSMD1 gene, thought to be a tumor suppressor, but involves multiple exons. Searching
the laboratory’s internal database of known CNVs yields no results, because no CNV of
that size and location has been reported. The laboratory must now attempt to interpret this
uncharacterized CNV, determining whether the mutation is a cause for concern.
1.3 Interpretation Variability
While the International System for Chromosome Nomenclature’s (ISCN) 2009 report
provides a system for reporting CNVs [12], no standard for interpeting uncharacterized
CNVs exists. Several factors are commonly thought to be important (e.g., a deletion is
considered to be more concerning than a duplication), but it is unclear to what extent each
factor is predictive. Furthermore, many factors known to be predictive are often unavailable
in initial screenings: CNV inheritance has been shown to strongly correlate with phenotypic
normalcy, but running full CNV screens on a patient’s parents is expensive, time-consuming,
and in many cases infeasible. This has led laboratories to consider various types of CNV
metrics, which may be combined in several ways to arrive at an interpretation.
Most concerningly, one study showed no concordance between interpretations of uncharac-
terized CNVs reported by different labs.[11] This study presented 11 different laboratories
with 13 patient cases, each with a clinical indication and a CNV. The labs were asked to
classify the CNVs using their standard practices. The results from each laboratory were then
aggregated to assess the variability of interpretation. The CNV from our case study was
interpreted as normal by three labs, abnormal by another three, and of “uncertain clinical
significance” by the remaining five. See Table 1.1 for the full listing of results, which
demonstrate a general lack of agreement between laboratories for uncharacterized CNV
interpretation. These results raise questions about the reproducibility and validity of the
tested techniques, and by extension, the current state of CNV characterization methods.
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Table 1.1: Variablility in CNV interpretation. The varied responses from independent CNV
classification efforts [11] demonstrate a lack of concordance between results.
Case CNV Normal Likely Benign Uncertain Abnormal
1 0.19/0.87a Mb dup., 3p26.3 6 0 4 1
2 0.81/0.89 Mb del., 8p23.2 3 0 5 3
3 0.17/0.39 Mb del., 3p26.2 5 0 6 0
4 0.46/1.0 Mb del., 6p11.2 6 1 3 1
5 0.19/2.9 Mb dup., 6q26 3 0 7 1
6 0.26/0.92 Mb dup., 6q27 5 0 5 1
7 0.63/0.79 Mb dup., 3p12.3 8 1 2 0
8 0.04/0.33 Mb del., 22q11.21 6 0 5 0
9 0.07/0.09 Mb del., 16p13.3 4 1 6 0
10 0.28/0.36 Mb dup., Xp11.23b 6 1 4 0
11 0.42/0.58 Mb del., 7q11.23 10 0 1 0
12 0.54/0.55 Mb dup., Xp22.33b 8 2 1 0
13 1.0/1.1 Mb dup., 5q21 4 2 5 0
Cases 1 through 6 are BAC array cases; 7 through 13 are oligonucleotide array cases.
aMinimum/maximum size,bFemale.
1.4 Goals
The goals of this research are two-fold: we seek to perform an evaluation of the CNV charac-
terization attempts made by others, then to apply more rigorous statistical and computational
methods in an attempt to improve on the state of the art techniques.
3
Chapter 2
Data
2.1 Copy Number Variation Identification
The CNVs used in our study were detected by hybridizing genomic DNA to a chromosomal
microarray (CMA)[13]. Each probe on the array maps to a specified location in the genome.
A set of probes that map to a contiguous segment of the genome are simultaneously perturbed
in the presence of a CNV. CNVs are identified by finding contiguous probes with elevated or
reduced intensities (see Figure 2.1). The sign of the magnitude of the copy number change
differentiates between deletions and duplications. CNV boundaries cannot be measured
exactly, but range within the sampling interval of the CMA.
The accuracy of detecting each CNV depends on the probe density, CNV size, and the
magnitude of the copy number change. Arrays with high probe density have more potential
to demonstrate evidence of CNVs, and achieve more accurate bounds on start and end points.
Similarly, larger CNVs will cross more probes, which also yields higher confidence. CNVs
with a large magnitude of copy number change are more accurately detected.
Several algorithms are commonly used for identifying CNVs in CMA data, including
PennCNV[14], QuantiSNP[15], HMMSeg[16], and cnvPartition (Illumina). Each software
package formulates the task as an optimization problem, using a Hidden Markov Model to
find optimal start and end locations for likely CNVs. A recent study by Tsuang et al. [17]
shows that each of these algorithms produce many false positives and false negatives, and
stresses the importance of the establishment of a standard for CNV validation.
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Figure 2.1: A visualization of two sections of CMA results, adapted from Miller et al. [13].
Each point corresponds to a probe on the CMA, and the thick gray bars indicate an identified
CNV. The vertical axis indicates the deviation of probe readings from a normal genome, and
the horizontal axis indicates position in the chromosome. Section A shows an identified
deletion on chromosome 7; section B shows an identified duplication on chromosome 11.
2.2 CNV Data
This study’s CNV data is taken from the set released by Itsara et al. [18] as well as the
International Standards for Cytogenomic Arrays (ISCA) consortium’s data in the restricted-
access database of Genotypes and Phenotypes (dbGaP)[19]. The Itsara set contains only
benign CNVs, while the ISCA set contains CNV data from affected patients. These two sets,
combined, account for 15,389 CNVs from 3167 patients. (See Table 2.1 for details). This
combination requires several assumptions about the makeup of each consitituent data set.
These assumptions are addressed in the discussion section.
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Table 2.1: CNV statistics. Summary statistics for the two sources of CNV data and the
combined set.
Patients Cases Mean CNVs/Patient Mean Size Std Dev Size
Itsara 2154 0 6.43 740.12 kb 1242.85 kb
ISCA 1013 1013 1.53 92.01 kb 140.22 kb
Combined 3167 1013 4.86 157.17 kb 459.29 kb
2.3 Supplemental Data
In addition to the raw CNV data, we integrate supplemental data from outside sources.
These sources are: the National Center for Biotechnology Information (NCBI) Entrez listing
of human genes [20], the Biomart webservice [21], the Search Tool for the Retrieval of
Interacting Genes/Proteins (STRING) protein interaction database [22], and the Gene Set
Enrichment Analysis (GSEA) database [23].
6
Chapter 3
Methods
In this section, we present a CNV scoring system currently in use in clinical settings, then
describe and justify our general approach.
3.1 Expert CNV Scoring
One current system for CNV interpretation, currently in use at the University of Washington[24],
is an expert-constructed, worksheet-based rubric that places a CNV into one of four classes.
The worksheet tabulates points for each of several CNV features, as shown in Table 3.1.
Points are added for features that indicate a higher likelihood of pathogenicity. Conversely,
points are subtracted for features that suggest the CNV is more likely benign.
We implement a facsimile of this scoring function in software to test its efficacy in uncharac-
terized CNV interpretation, and to serve as a baseline against which other approaches can be
compared. Our version mimics the scoring of the original for the first four features only. We
disregard features that are relevant only to characterized CNVs, because our study focuses
on the problem of interpreting uncharacterized CNVs. We also disregard subjectively scored
features, which are not meaningully implementable in software.
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Table 3.1: Worksheet point allocation. Each CNV feature has the potential to contribute
points from the listed ranges, but the lack of secondary data (features 6,7,9) for uncharacter-
ized CNVs limits the features under consideration.
Range Uncharacterized
Deletion/Duplication 0 to 1 0 to 1
Size 0 to 3 0 to 3
Number of Genes -1 to 4 -1 to 4
Genes Interruption 0 to 1 0 to 1
Gene Roles* 0 to 2 0 to 2
Known Del/Dup Syndrome 0 to 1 0
Signature/Decipher Cases -1 to 2 0
Segmental Duplications* -1 to 0 -1 to 0
Benign CNV Overlap -3 to 1 0
*These features, while available for uncharacterized CNVs, are scored too subjectively to be
used in a software implementation.
Table 3.2: Worksheet score ranges. A CNV’s score is the sum of the assigned points for
each feature, which provides a basis for labelling.
Score CNV Label
≤ 0 Do Not Report (Normal)
1-4 No Known Pathogenic Imbalances
5-8 Unclear Clinical Significance
> 8 Likely Pathogenic
3.2 Reference Range Approach
We hypothesize that significant improvements can be made to the expert scoring system
discussed in the previous section by using statistical methods to construct a reference range
(or reference interval)[25] for benign CNVs. Our basic approach is to,
1. Model the probability density of each CNV descriptor amongst the set of benign
CNVs.
2. Score each CNV by the sum of the negative log likelihood according these densities.
score(CNV ) =− ∑
f eature
logP( f eature(CNV ) |benign) . (3.1)
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3. Assign the score of the highest scoring CNV to each patient.
score(patient) = max
CNV∈patient
[score(CNV )] , (3.2)
4. Declare a patient’s CNV abnormal if their score is above the 95th percentile (that is,
outside the reference interval) of scores for normal patients.
The reference range is a well-established strategy in medical practice[25, 26, 27, 28, 29]. A
reference range is simply a confidence interval (generally 95%) for the distribution of test
results for a control group, which provides a common-sense framework for interpreting the
results of clinical tests. The interval is used to provide context for the results of the same
test when performed on a patient. A measurement within the reference range is likely to be
normal (that is, unlikely to be diagnostically relevant), and a measurement outside the range
may merit further investigation.
Our approach measures the feature densities of benign CNVs, whereas a more complete
Bayesian treatment is to score CNVs by their likelihood of being pathogenic given their
features,
score(CNV ) = P(pathogenic|F) = P(F |pathogenic)P(pathogenic)
P(F)
. (3.3)
However, direct estimation of the distribution of pathogenic CNVs is difficult, as we do not
have a clear strategy for labeling CNV-level data as pathogenic. Instead, each patient’s set
of CNVs is associated with the patient’s known clinical phenotype. As such, while all the
CNVs of a normal patient can be safely labeled benign, labels for the CNVs of pathogenic
patients are unknown.
3.3 Likelihood Scoring
In an attempt to improve the accuracy of CNV interpretation, we consider several features
in this probabilistic framework. For each feature, we define the feature density function
P( f eature(CNV ) |benign) used in Equation 3.1. We begin by examining the four CNV
features used in the expert scoring rubric, then move on to novel CNV features.
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3.3.1 Duplication vs Deletion
The simplest CNV feature notes the sign of the magnitude of the copy number change. We
model this binary feature with a Bernoulli distribution, counting the number of each type in
the set of benign CNVs, B. This gives rise to the probabilility density function
P(dup|benign) = |duplications∩B||B| = 1−P(del|benign) . (3.4)
3.3.2 Size
In a similar fashion, we consider the probability density for the size of a benign CNV.
Visualizing the histogram of benign CNV sizes suggests an exponential distribution (Figure
3.1), which, unlike a Gaussian distribution, ensures zero probability of any negative value.
Figure 3.1: Frequency of benign CNV sizes. λ ≈ 1740 .
This produces the density function
P(size = x|benign) = λe−λx, (3.5)
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where the rate parameter λ is determined using fitting of first moment,
λ = E (sizes)−1 =
|B|
∑CNV∈B [size(CNV )]
. (3.6)
Better estimates might be obtained using a maximum likelihood estimator for λ , but we
found this fit good enough for our purposes.
3.3.3 Split and Spanned Genes
The last two features from our implementation of the expert worksheet consider the number
of genes a CNV overlaps, broken into counts for spanned (complete overlap) and split (partial
overlap) genes. As with the previous feature, we visualize the distribution of spanned genes
among the benign CNV set (Figure 3.2), and observe that the exponential distribution fits
resonably well. The split genes feature can clearly only take on one of three values, so we
use an empirical distribution, counting the frequency of each number of gene splits over the
set of benign CNVs.
As such, the density function from Equation 3.5 may be reused for the spanned genes feature,
with a different rate parameter λ based on the expected value of the number of spanned
genes in the benign set. The density function for the split genes feature resembles Equation
3.4, taking the form
P(splits = x|benign) = |{CNV ∈ B|splits(CNV ) = x}||B| . (3.7)
3.3.4 Gene Density Scoring
We now turn to new CNV features, to test whether additional types of information are
useful for discriminating benign from pathogenic CNVs. The first such feature considers the
specific genes disrupted by a CNV, computing a density for each benign CNV’s disrupted
genes. The least likely of a CNV’s genes is selected to represent the CNV, resulting in the
function
P(genes|benign) = 1+ min
g∈genes [countB (g)] (3.8)
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where countB (g) is the number of benign CNVs that overlap gene g. One is added to the
minimum count to ensure that the function’s range is strictly greater than zero, because the
overall CNV scoring function (Eq. 3.1) takes the logarithm of this likelihood.
3.3.5 Network Density Scoring
The gene density scoring in the previous section is perhaps too restrictive, counting only
direct matches between overlapped genes. To blur this relationship somewhat, we now
consider the gene network of a CNV, a superset of the CNV’s directly disturbed genes. Gene
networks are the union of the neighborhoods of a CNV’s disturbed genes. A gene’s neigh-
borhood is constructed using the connection information from the STRING database[22],
finding likely, immediate neighbors in the connectivity graph. (That is, with edge p-value of
at least 0.95 and a graph distance of at most 1.)
We modify the density function described in Equation 3.8 only slightly, producing
P(network|benign) = 1+ min
g∈network
[countB (g)] (3.9)
where countB (g) now represents a weighted number of benign CNV networks that include
gene g. As before, any benign CNV that overlaps g contributes 1 to the count, but CNVs
with g as a neighbor gene contribute 12 . This simple weighting scheme encodes the relative
importance of the genes in a CNVs network.
3.4 Gene Set Scoring
Similar to the networks created from STRING data in the previous section, Gene Set
Enrichment Analysis (GSEA)[23] can be used to produce a set of statistically significant
gene sets that may be representative of phenotypic effects of the CNV. This gene-set feature
provides another way of observing the effect of disturbed genes in a less-restricted manner.
We modify the density function in Equation 3.8 again, creating
P(geneset|benign) = 1+ min
gs∈geneset [countB (gs)] (3.10)
12
where countB (gs) is the number of benign CNVs with a disturbed gene in gene-set gs.
This method of scoring operates at a higher level of abstraction than the previous two,
focusing not on individual genes but instead on the greater biological processes at work. We
hypothesize that this will be beneficial in cases where an incomplete model of benign CNVs
hinders the performance of the other gene-based scoring functions.
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(a) Spanned gene frequency. λ ≈ 18.6 .
(b) Split gene frequency.
Figure 3.2: Frequency of benign CNV gene interactions.
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Chapter 4
Results
The following experimental results are generated using leave-one-out cross validation to
assess patient classification accuracy. The classification results are visualized on Receiver
Operating Characteristic (ROC) plots for comparison, with a dotted line indicating a 95%
specificity level and a dashed no-indication line.
4.1 How Effective is Expert Scoring?
Figure 4.1: Expert worksheet scoring classification results.
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This experiment shows that our version of the expert worksheet classifier does not adequately
separate pathogenic from benign CNVs. As shown in Figure 4.1, only 30.0% sensitivity is
achieved at a specificity of 95%. This result aligns with the survey data presented in Figure
1.1, in which a general lack of concordance between classification attempts is observed. This
confirms our suspicion that, for the problem of assessing uncharacterized CNVs, current
clinical practices are not adequate.
4.2 Which Features are Most Effective?
This experiment attempts to improve on the expert worksheet scoring system by applying
our more statistically rigorous approach (described in Section 3.2) to an expanded set CNV
features. First, we score each feature independently (Figure 4.2, Table 4.1).
16
(a) Duplication vs Deletion (b) Size
(c) Gene Overlap Counts (d) Gene Density
(e) Network Density (f) Gene Set Density
Figure 4.2: Independent feature scoring classification results.
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Table 4.1: Independent feature scoring classification results. Sensitivity values are measured
at the 95% specificity level.
Feature Sensitivity Area Under ROC
Dup/Del 0.0% 0.259
Size 43.3% 0.704
Genes Spanned 18.5% 0.576
Genes Split 0.4% 0.162
Gene Density 5.1% 0.504
Network Density 25.3% 0.815
Gene Set Density 10.9% 0.601
These results provide a clear look at which features best discriminate between pathogenic
and benign CNVs. We observe improvement over the expert scoring function using only
CNV size, a result that underscores the utility of our statistical approach. This result follows
the intuition that, generally, large CNVs have more of an effect on biological processes than
small CNVs. Other features, like the number of spanned genes, show some discriminative
ability but fail to stand on their own.
As expected, the network density and gene set density features outperform the basic gene
density feature. This confirms our hypothesis that restricting comparison to shared gene
overlaps does not capture the full complexity of the biological interaction.
4.3 Worksheet Feature Correlation
To further compare our approach against the expert scoring system, we examine the correla-
tion between the expert CNV scores and a function in our framework composed of the same
four features, which we refer to as the “probabilistic worksheet” scoring function (Figure
4.3).
We measure a positive correlation between the two CNV scoring functions for both sets of
CNVs. This demonstrates that our statistical approach does indeed emulate the behavior
of the expert scoring worksheet. We further examine this relationship by plotting the
classification results of the two functions on a ROC curve in Figure 4.4. While this result
indicates that the probabilistic model failed to improve upon our baseline with this feature
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Figure 4.3: CNV scoring correlation. A ±0.2 random jitter is applied to the integer
worksheet scores for added clarity. Pearson correlation coefficients (R) for pathogenic and
benign sets are 0.593 and 0.552, respectively.
combination, it also provides evidence that our framework produces reasonable CNV scoring
functions.
4.4 Feature Combination
We now select the most promising features from the independent feature experiments for
use in a combined-feature “fusion” scoring function. The resulting function follows the
form of Equation 3.1, summing the negative log-likelihoods of each feature.
Figure 4.5 reveals that an unweighted sum of size, spanned genes, network, and gene-set
density scores actually performs worse than any of its individual constituent features. This
indicates that the sum of feature log-likelihoods will require non-uniform weight coefficients,
to model the relative influence of each log-likelihood. Many methods exist for learning the
coefficients of this weighted sum, but that problem is beyond the scope of this thesis and is
discussed more fully below.
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Figure 4.4: Probabilistic and expert worksheet scoring classification results. The probabilis-
tic worksheet achieves slightly lower sensitivity at 95% specificity, but generally follows the
expert scoring function closely in the critical 80%-100% specificity range.
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Figure 4.5: Fusion scoring classification results. The combined-feature scoring function,
made up of size, spanned genes, network density, and gene-set density features, achieves
only 19.8% sensitivity at 95% specificity. Total area under the ROC curve is 0.480.
21
Chapter 5
Discussion
The results of our experiments provide insight into the current state of uncharacterized CNV
classification. It is clear that current clinical techniques do not yield trustworthy interpreta-
tions, but the results of our experiments with CNV features in a statistical framework show
promise. Attempts to combine features reveal the need for non-uniform feature likelihood
weights, an additional learning problem discussed in more detail below.
The methods of this study have some limitations, stemming from mixed data sources,
unknown labels at the CNV level, and independence assumptions made on CNV features.
5.1 Heterogeneous Data
The first limitation relates to the method of combining datasets, as it is difficult to tell whether
observed distinctions between CNVs of affected and normal patients are true differences or
simply artifacts of different CNV identification and reporting methods. CNVs from both
the Itsara and ISCA sets were generated using CMA, but not necessarily with the same
sampling parameters. As discussed in Section 2.1, the density of probe coverage on each
chromosome introduces variability in CNV identification, affecting the accuracy of CNV
boundaries as well as the resolution at which CNVs can be reliably measured. More samples
from the array afford higher confidence, so different screens from the same patient tend to
agree the larger CNVs, but may not be able to reproduce smaller mutations.
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Future work would benefit from a standardized database of characterized CNVs as proposed
by Tsuchiya et al. [11], with guarantees about the methods of data collection and CNV iden-
tification. Such a database would have immediate utility in the clinic, while also providing
a reliable data set for large-scale CNV studies. This task is nontrivial, however. Analysis
of the Database of Genomic Variants revealed that 88% of previously reported CNVs were
inaccurately sized[30], a symptom of the imprecise and unstandardized CNV detection
methods used in various laboratories. CMA whole-genome hybridization techniques have
improved CNV detection significantly, but data inaccuracies will continue to plague CNV
studies until a gold standard is established.
5.2 Multiple Instance Problem
The second limitation arises from the lack of ground-truth labels for individual CNVs. In
an ideal scenario, the problem of CNV characterization could be simplified to a binary
classification: a CNV either contributes to phenotypic abnormalities or does not. Many
well-known machine learning techniques are suited to binary classification, and are easy
to apply to a variety of problems. However, in the case of CNV characterization, instance
labels are available only at the patient level. This introduces the multiple instance problem:
a pathogenic patient may have many CNVs, and it is unknown which or how many of them
are contributory to the observed phenotypic abnormality.
Multiple instance learning (MIL) was first introduced as such by Dietterich and Lathrop
[31] in 1997, and remains an active research area today[32, 33]. Early applications of
MIL focused on drug activity prediction tasks, then expanded to scene classification in
images[34], and now MIL techniques pervade machine learning.
Several algorithms of varying complexities have been proposed for addressing the multiple
instance problem[35, 36], but the scoring functions in this study deal with the multiple
instance problem much more simply: scoring each of a patient’s CNVs individually, then
choosing the most extreme score for patient classification. This practice follows from a sim-
ple interpretation of the underlying biological processes: one key breakdown in an important
pathway will produce detrimental effects, regardless of other mutations. This allows one
model to be constructed for both patient phenotype prediction and CNV characterization.
23
However, the approach does not account for cases in which pathogenicity arises from a
combination of otherwise benign CNVs. Few such cases have been identified, and the
relevance of this “combinatorial pathogenicity” is unclear. As such, further study will be
required to establish the full importance of these potential CNV interactions.
5.3 Reference Ranges and Feature Independence
The multiple instance problem complicates a full Bayesian treatment of the data, for which
several methods of statistical MIL have been developed [37, 38, 39]. Our approach, however,
draws from the precedent set by medical practice of using a reference range to model the
set of known benign CNVs, as described in Section 3.2. This relies on the assumption
that the features used to construct the reference range are conditionally independent, given
benign CNVs. Clearly, this is not true for the size of a CNV and number of genes it spans.
This is a significant limitation of our method, but, as is the case in many machine learning
applications, the benefit of a simple model– a result of the naive independence assumption–
outweighs the costs of mathematical correctness.
5.4 Likelihood Weight Learning
As previously discussed, our model suffers from the assumption that all feature log-
likelihoods contribute equally to a CNV pathogenicity score. To learn these weights,
a second layer of learning should be added to the model. Under our framework, using k
different CNV features, it is simple to consider CNVs as k-dimensional vectors in feature
log-likelihood space. Our current approach, therefore, scores a CNV by the negative sum
of its vector. A more effective approach might instead use the MIL algorithms referred to
in Section 5.2, like the support vector machine method described in Andrews et al. [36].
A less rigorous treatment might sidestep the multiple instance problem by choosing the
least likely benign CNV with the naive method, associating the patient label with that CNV,
then learning weights using standard techniques. The discriminative power of individual
feature scoring in this study suggests that future work on feature combination may lead to
significant improvements in CNV interpretation.
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Chapter 6
Conclusion
Copy Number Variation analysis has recently become a viable tool for patient diagnosis
in clinical settings, thanks to the development of relatively inexpensive and accurate array-
based detection methods. The wealth of CNV data being generated is underutilized, however,
especially in the case of uncharacterized CNVs. This thesis performs a detailed examination
of one assessment technique currently in clinical use, then presents a novel statistical
method for CNV interpretation. Experimental results confirm previous findings that current
clinical CNV interpretation methods are inadequate and that there is significant room for
improvement. The results indicate the effectiveness of a principled, feature-based, statistical
framework for uncharacterized CNV interpretation, which future studies can expand upon
to construct more reliable classifiers.
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